| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Health Foundation, Valhalla, New York 10595 [G. C. H., M. J. I., K. J., L. R., O P. K., G. M. W.], and Adria Laboratories, Columbus, Ohio 43216 [A. R. I.]
2 To whom requests for reprints should be addressed, at American Health Foundation, 1 Dana Road, Valhalla, NY 10595.
The hepatoproliferative effects of 2 antiestrogens, tamoxifen and toremifene, were compared in a sequential 15-month study in which 2 doses of each compound were administered by daily gavage to female Sprague-Dawley rats for up to 12 months. The doses were 11.3 and 22.6 mg/kg for tamoxifen and 12 and 24 mg/kg for toremifene. There were scheduled sacrifices at 3, 6, 12, and 15 months, the latter including a 3-month recovery period from the 12th through the 14th month. In the chronic toxicity study, tamoxifen at 22.6 mg/kg produced 100% incidence of hepatocellular carcinoma at the 12- and 15-month sacrifice intervals and 67% and 71% incidences at the 11.3-mg/kg dose. Sequential observations showed an increased incidence of glutathione S-transferase-positive foci of hepatocellular alteration by 3 months with tamoxifen in the absence of hepatotoxicity, with the first liver carcinoma appearing by 6 months of treatment. Unscheduled deaths occurring beyond 7.5 months in the tamoxifen treated groups were due in almost all cases to liver cancer. In striking contrast, toremifene did not produce any hepatoproliferative effects at 12- and 24-mg/kg dose levels, nor in a pilot study at 48 mg/kg. The 24-mg/kg dose of toremifene exerted an inhibiting effect on foci of hepatocellular alteration in rat liver detectable by glutathione S-transferase immunohistochemistry at 3 months and by conventional histology at 12 months. An antiproliferative effect was also evident in mammary gland and anterior pituitary where both toremifene and tamoxifen suppressed tumor incidence in comparison to the control group. The ability of these drugs to modify rat liver DNA after p.o. administration was investigated using the 32P-postlabeling assay. Administration of tamoxifen at 45 mg/kg for 7 days produced liver DNA nucleoside modifications represented by 7 spots on the autoradiogram. Unlike tamoxifen, toremifene did not produce any modified bases in rat liver DNA detectable by the 32P-postlabeling technique. The dose levels of tamoxifen that are strongly hepatocarcinogenic in the rat are compared with doses used in humans in various applications. Taking internal drug exposure into account, we conclude that the margin of safety for use of tamoxifen as an endocrine prophylactic agent for healthy, but breast cancer prone, women is questionable.
1 This research was supported financially by Adria Laboratories, Columbus, OH, and Farmos Group, Ltd., Turku, Finland.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 4/ 8/93. Accepted 7/26/93.
This article has been cited by other articles:
|
|
 |
|
  S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen Cancer Res., August 1, 2003; 63(15): 4402 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Raghow, M. Z. Hooshdaran, S. Katiyar, and M. S. Steiner Toremifene Prevents Prostate Cancer in the Transgenic Adenocarcinoma of Mouse Prostate Model Cancer Res., March 1, 2002; 62(5): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. WOLFF and N. E. DAVIDSON Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 80 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. DUNN, M. ANTHONY, S. SHERMAN, and J. P. COSTANTINO Conclusions: Considerations Regarding SERMs Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 352 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Fan and J. L. Bolton Bioactivation of Tamoxifen to Metabolite E Quinone Methide: Reaction with Glutathione and DNA Drug Metab. Dispos., June 1, 2001; 29(6): 891 - 896. [Abstract] [Full Text]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen Cancer Res., May 1, 2001; 61(10): 3925 - 3931. [Abstract] [Full Text]
|
|
|
|
|
|
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats Carcinogenesis, April 1, 2001; 22(4): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Lee, J. M. Schafer, K. Yao, G. England, R. M. O’Regan, A. D. L. Reyes, and V. C. Jordan Cross-Resistance of Triphenylethylene-type Antiestrogens but not ICI 182,780 in Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., December 1, 2000; 6(12): 4893 - 4899. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al. Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Klotz, H. J. Hacker, D. Klingmuller, P. Bannasch, U. Pfeifer, and F. Dombrowski Hepatocellular Alterations after Intraportal Transplantation of Ovarian Tissue in Ovariectomized Rats Am. J. Pathol., May 1, 2000; 156(5): 1613 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Komi and O. Lassila Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells Blood, May 1, 2000; 95(9): 2875 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Carthew, R. E. Edwards, B. M. Nolan, E. A. Martin, R. T. Heydon, I. N.H. White, and M. J. Tucker Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia Carcinogenesis, April 1, 2000; 21(4): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients Carcinogenesis, April 1, 2000; 21(4): 845 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White The tamoxifen dilemma Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]
|
|
|
|
|
|
I. Terashima, N. Suzuki, and S. Shibutani Mutagenic Potential of {{alpha}}-(N2-Deoxyguanosinyl)tamoxifen Lesions, the Major DNA Adducts Detected in Endometrial Tissues of Patients Treated with Tamoxifen Cancer Res., May 1, 1999; 59(9): 2091 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Williams Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, April 21, 1999; 91(8): 722 - 722. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Beland, L. P. McDaniel, and M. M. Marques Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo Carcinogenesis, March 1, 1999; 20(3): 471 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Osborne, A. Hewer, W. Davis, A. J. Strain, A. Keogh, I. R. Hardcastle, and D. H. Phillips Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells Carcinogenesis, February 1, 1999; 20(2): 293 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Osborne Tamoxifen in the Treatment of Breast Cancer N. Engl. J. Med., November 26, 1998; 339(22): 1609 - 1618. [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yao and V. C. Jordan Questions about Tamoxifen and the Future Use of Antiestrogens Oncologist, April 1, 1998; 3(2): 104 - 110. [Abstract] [Full Text]
|
|
|
|
|
|
C. MALTONI, F. MINARDI, C. PINTO, F. BELPOGGI, and L. BUA Results of Three Life-Span Experimental Carcinogenicity and Anticarcinogenicity Studies on Tamoxifen in Rats Ann. N.Y. Acad. Sci., December 26, 1997; 837(1): 469 - 512. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C Eagle Manufacturer's reply BMJ, October 12, 1996; 313(7062): 945 - 945. [Full Text]
|
|
|
|
|
|
V C Jordan Safety of tamoxifen BMJ, May 28, 1994; 308(6941): 1438 - 1438. [Full Text]
|
|
|
|
|
|
G M Williams Safety of tamoxifen BMJ, February 19, 1994; 308(6927): 534 - 534. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
